BioTime (BTX) Is Now Covered By Oppenheimer. What can We Expect?


Investors sentiment increased to 1.39 in Q3 2018. Its up 0.24, from 1.15 in 2018Q2. It increased, as 9 investors sold BioTime, Inc. shares while 19 reduced holdings. 16 funds opened positions while 23 raised stakes. 55.13 million shares or 0.24% less from 55.26 million shares in 2018Q2 were reported.

Virtu Fin Limited Liability Corporation owns 13,143 shares. Manufacturers Life Ins Commerce The reported 68,878 shares. Morgan Stanley holds 199,610 shares or 0% of its portfolio. American Interest Gru reported 59,409 shares or 0% of all its holdings. New York State Common Retirement Fund owns 69,500 shares. United Services Automobile Association invested in 0% or 25,411 shares. Deutsche Retail Bank Ag invested in 192,699 shares or 0% of the stock. 33,476 were accumulated by Parametric Port Associate Ltd Limited Liability Company. Ameritas Inv Prtnrs stated it has 0% in BioTime, Inc. (NYSEAMERICAN:BTX). Two Sigma Secs Ltd Company accumulated 13,041 shares. Northern invested 0% in BioTime, Inc. (NYSEAMERICAN:BTX). Jefferies Grp Incorporated Ltd Liability Company accumulated 117,571 shares. Voya Inv Mngmt Llc invested in 32,496 shares or 0% of the stock. State Board Of Administration Of Florida Retirement Systems invested in 22,784 shares or 0% of the stock. Fincl Bank Of Mellon reported 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX).

Since September 11, 2018, it had 1 buy, and 0 insider sales for $3,769 activity.

Why Has Oppenheimer Given BioTime (BTX) a $3.5 Price Target

In an analyst report published on Tuesday, 11 December, Oppenheimer analyst has today has started coverage for BioTime (BTX) shares with a Outperform rating. The price target is set to $3.5.

The stock decreased 1.54% or $0.02 during the last trading session, reaching $1.28. About 534,533 shares traded or 13.89% up from the average. BioTime, Inc. (BTX) has declined 29.39% since December 12, 2017 and is downtrending. It has underperformed by 29.39% the S&P500.

Analysts await BioTime, Inc. (NYSEAMERICAN:BTX) to report earnings on March, 21. They expect $-0.07 earnings per share, up 12.50 % or $0.01 from last year’s $-0.08 per share. After $-0.07 actual earnings per share reported by BioTime, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $162.51 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It currently has negative earnings. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

More notable recent BioTime, Inc. (NYSEAMERICAN:BTX) news were published by: which released: “BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies – Business Wire” on September 25, 2018, also with their article: “BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer – Business Wire” published on September 18, 2018, published: “GlobalSCAPE Regains Compliance with NYSE American Continued Listing Standards – Business Wire” on June 25, 2018. More interesting news about BioTime, Inc. (NYSEAMERICAN:BTX) were released by: and their article: “BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences – Business Wire” published on August 28, 2018 as well as‘s news article titled: “AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London – Business Wire” with publication date: May 17, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.